{"id":"NCT01724528","sponsor":"Menarini Group","briefTitle":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies","officialTitle":"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-11-09","resultsPosted":"2014-11-03","lastUpdate":"2014-11-03"},"enrollment":346,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Tumor Lysis Syndrome"],"interventions":[{"type":"DRUG","name":"Febuxostat","otherNames":["Adenuric"]},{"type":"DRUG","name":"Allopurinol","otherNames":["Zyloric"]}],"arms":[{"label":"Febuxostat","type":"EXPERIMENTAL"},{"label":"Allopurinol","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether febuxostat is superior to allopurinol in the prevention of tumor lysis syndrome (TLS) in patients with hematological malignancies at intermediate or high risk of TLS (according to Cairo-Bishop classification) who undergo chemotherapy","primaryOutcome":{"measure":"Serum Uric Acid (sUA) Level Control","timeFrame":"8 days","effectByArm":[{"arm":"Febuxostat","deltaMin":514,"sd":225.71},{"arm":"Allopurinol","deltaMin":708,"sd":234.42}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26216382"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":173},"commonTop":["Neutropenia","Anaemia","Leukopenia","Thrombocytopenia","Nausea"]}}